Interindividual Variability in the Prevalence of OPRM1 and CYP2B6 Gene Variations May Identify Drug-Susceptible Populations

TY - JOUR

T1 - Interindividual Variability in the Prevalence of OPRM1 and CYP2B6 Gene Variations May Identify Drug-Susceptible Populations

AU - Bunten, H.

AU - Liang, W. J.

AU - Pounder, D. J.

AU - Seneviratne, C.

AU - Osselton, D.

PY - 2011/9

Y1 - 2011/9

N2 - Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and µ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.

AB - Methadone is used worldwide for the treatment of heroin addiction; however, fatal poisonings are increasingly reported. The prevalence of CYP2B6 and µ-opioid receptor (OPRM1) gene variations were examined between a postmortem population where the deaths were associated with methadone and a live nondrug-using control population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was higher in the postmortem population, but the difference was not significant (P = 0.92). The CYP2B6 T750C promoter variation was similar in frequency for both populations. Linkage between T750C and CYP2B6*6 was identified for both populations (P < 0.01). The prevalence of the OPRM1 A118G variation was significantly higher in the control population (P = 0.0046), which might indicate a protective mechanism against opioid toxicity. Individual susceptibility to methadone may be determined by screening for CYP2B6*6.

KW - MU-OPIOID-RECEPTOR

KW - SINGLE-NUCLEOTIDE POLYMORPHISM

KW - GENDER-DIFFERENCES

KW - DOPAMINE RELEASE

KW - SEX-DIFFERENCES

KW - ASSOCIATION

KW - ALCOHOL

KW - ABUSE

KW - A118G

KW - AMPHETAMINE

U2 - 10.1093/anatox/35.7.431

DO - 10.1093/anatox/35.7.431

M3 - Article

SN - 0146-4760

VL - 35

SP - 431

EP - 437

JO - Journal of Analytical Toxicology

JF - Journal of Analytical Toxicology

IS - 7

ER -